<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473665</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR3505</org_study_id>
    <nct_id>NCT03473665</nct_id>
  </id_info>
  <brief_title>Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis</brief_title>
  <official_title>Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6-week randomized, double-blind trial of 4 different non-steroidal
      anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of
      pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion
      and exclusion criteria will be randomized into one of the four arms after an initial one week
      washout period, including: 1) indomethacin 75mg Q12H; 2) diclofenac 75mg Q12H; 3) meloxicam
      7.5mg Q12H; 4) celecoxib 200mg Q12H. The treatment length will be 6 weeks. Primary outcome is
      the change of pain score from baseline to week 4 and to week 6.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of pain score</measure>
    <time_frame>at week 4 vs. at week 6</time_frame>
    <description>change of pain score by numerical rating score from baseline [scale range: 0 (better) -10 (worse)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of BASDAI</measure>
    <time_frame>at week 4 vs. at week 6</time_frame>
    <description>change of Bath Ankylosing Spondylitis Disease Activity Index from baseline [scale range: 0 (better) -10 (worse)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of BASFI</measure>
    <time_frame>at week 4 vs. at week 6</time_frame>
    <description>change of Bath Ankylosing Spondylitis Functional Index from baseline [scale range: 0 (better) -10 (worse)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of ASDAS</measure>
    <time_frame>at week 4 vs. at week 6</time_frame>
    <description>change of Ankylosing Spondylitis Disease Activity Score from baseline [composite score: 0 (no disease activity) - 6.5 (very high disease activity)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Response to Therapy (PGART)</measure>
    <time_frame>at week 6</time_frame>
    <description>patient's global assessment of effectiveness of a treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Indomethacin</arm_group_label>
    <other_name>INDO</other_name>
    <other_name>Indomethacin ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Diclofenac</arm_group_label>
    <other_name>DIC</other_name>
    <other_name>Diclofenac DR</other_name>
    <other_name>Voltarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Meloxicam</arm_group_label>
    <other_name>MLX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>CEL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of ankylosing spondylitis (AS) by treating rheumatologists, or a
             diagnosis of axial spondyloarthritis (axSpA) with a pelvis MRI with significant bone
             marrow edema on STIR sequences;

          -  Minimum of 18 years old;

          -  Are taking NSAIDs on a regular basis for AS or axSpA (defined as more than 20 days in
             the past month) and willing to withhold medication for one week; or having active
             symptoms that require initiation of NSAIDs;

          -  Concomitant anti-rheumatic drugs are allowed, if the dose has been stable for the past
             three months;

          -  Have active disease after initial washout period, defined by BASDAI &gt;=4/10, or back
             pain numerical rating scale (NRS)&gt;=4/10

        Exclusion Criteria:

          -  Patients who have concurrent rheumatic diseases other than AS or axSpA;

          -  Patients who have oral corticosteroid in the past two weeks; patients who have acute
             peripheral arthritis;

          -  Patients with a fibromyalgia score &gt;= 13;

          -  Patient with extensive cardiac history, history of gastrointestinal bleeding that
             required blood transfusion, chronic kidney diseases, abnormal liver function tests; or
             female patients who are pregnant.

        Use of low-dose of aspirin (&lt;100mg daily) is allowed in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runsheng Wang, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Depender</last_name>
    <phone>212-305-4114</phone>
    <email>cd2686@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Runsheng Wang, MD, MHS</last_name>
    <phone>212-342-2706</phone>
    <email>rw2646@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Depender</last_name>
      <phone>212-305-4114</phone>
      <email>cd2686@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Runsheng Wang, MD, MHS</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <keyword>ankylsoing spondylitis</keyword>
  <keyword>spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

